@article{ajmcr20221075,
author={Shibusawa, Motoharu},
title={Cytogenetic Remission in Response to Dasatinib Monotherapy in Mixed-phenotype Acute Leukemia with t(9;22)(q34.1;q11.2) Translocation},
journal={American Journal of Medical Case Reports},
volume={10},
number={7},
pages={181--184},
year={2022},
url={http://pubs.sciepub.com/ajmcr/10/7/5},
issn={2374-216X},
abstract={The case of a 44-year-old Japanese woman diagnosed with mixed-phenotype acute leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 (MPAL-BA) is reported. Her white blood cell count was 5,100/¦ÌL with 13.0% blasts; positive for CD34, HLA-DR, MPO, CD33, CD19, cytoplasmic (cy) CD79a, CD22, CD10, and TdT; and negative for cyCD3. G-band cytogenetic analysis detected a normal karyotype. Fluorescence in situ hybridization detected BCR-ABL1 (9.0%) and a minor BCR-ABL1 mRNA at 4.2 ¡Á 10<SUP>4</SUP> copies/¦Ìg RNA. The patient was treated with dasatinib monotherapy (140 mg daily). Bone marrow examination revealed cytogenetic remission (CyCR) with minor BCR-ABL1 mRNA detected at 1.1 ¡Á 10<SUP>3</SUP> copies /¦Ìg RNA on day 31. No adverse events of dasatinib therapy were observed. MPAL-BA is very rare and dasatinib monotherapy efficacy for this diagnosis was previously unknown. The patient achieved CyCR with dasatinib monotherapy as first-line treatment. The present case suggests that dasatinib monotherapy may be effective and safe for MPAL-BA induction therapy.},
doi={10.12691/ajmcr-10-7-5}
publisher={Science and Education Publishing}
}